Tags

Type your tag names separated by a space and hit enter

Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord. 2019 Feb; 28:98-100.MS

Abstract

Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system and is one of the main causes of disability in young adults. Alemtuzumab is a humanized monoclonal anti CD52 antibody approved for active relapsing-remitting (RR) multiple sclerosis (MS) exerting its strong clinical efficacy by a specific pattern of depletion of CD52-positive immune cells followed by their repopulation. As with most infused biological therapies, infusion-associated reaction (IAR) are frequently reported as adverse events for alemtuzumab treatment. In addition to cellular depletion, bystander effects including transient cell activation and triggered cytokine release are thought to cause alemtuzumab-specific IARs. We describe acute laboratory changes during first alemtuzumab infusion week in a RRMS patient, underling acute changes in immunological and routine laboratory parameters.

Authors+Show Affiliations

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy. Electronic address: anielloiovino@msn.com.Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy.Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy.Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy.Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

30580038

Citation

Iovino, Aniello, et al. "Acute Leukocytosis During Alemtuzumab Treatment in Patients With Active Relapsing-remitting Multiple Sclerosis." Multiple Sclerosis and Related Disorders, vol. 28, 2019, pp. 98-100.
Iovino A, Aruta F, Carotenuto A, et al. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2019;28:98-100.
Iovino, A., Aruta, F., Carotenuto, A., Manganelli, F., & Iodice, R. (2019). Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 28, 98-100. https://doi.org/10.1016/j.msard.2018.12.024
Iovino A, et al. Acute Leukocytosis During Alemtuzumab Treatment in Patients With Active Relapsing-remitting Multiple Sclerosis. Mult Scler Relat Disord. 2019;28:98-100. PubMed PMID: 30580038.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis. AU - Iovino,Aniello, AU - Aruta,Francesco, AU - Carotenuto,Antonio, AU - Manganelli,Fiore, AU - Iodice,Rosa, Y1 - 2018/12/18/ PY - 2018/08/09/received PY - 2018/12/14/revised PY - 2018/12/16/accepted PY - 2018/12/24/pubmed PY - 2019/6/14/medline PY - 2018/12/24/entrez KW - Alemtuzumab KW - IAR KW - Leukocytosis KW - Multiple sclerosis SP - 98 EP - 100 JF - Multiple sclerosis and related disorders JO - Mult Scler Relat Disord VL - 28 N2 - Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system and is one of the main causes of disability in young adults. Alemtuzumab is a humanized monoclonal anti CD52 antibody approved for active relapsing-remitting (RR) multiple sclerosis (MS) exerting its strong clinical efficacy by a specific pattern of depletion of CD52-positive immune cells followed by their repopulation. As with most infused biological therapies, infusion-associated reaction (IAR) are frequently reported as adverse events for alemtuzumab treatment. In addition to cellular depletion, bystander effects including transient cell activation and triggered cytokine release are thought to cause alemtuzumab-specific IARs. We describe acute laboratory changes during first alemtuzumab infusion week in a RRMS patient, underling acute changes in immunological and routine laboratory parameters. SN - 2211-0356 UR - https://www.unboundmedicine.com/medline/citation/30580038/Acute_leukocytosis_during_alemtuzumab_treatment_in_patients_with_active_relapsing_remitting_multiple_sclerosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(18)30555-8 DB - PRIME DP - Unbound Medicine ER -